Bull's eye maculopathy is a circular retinal pattern tied to drug-induced toxicity. Classic culprits include chloroquine and hydroxychloroquine, with risk rising with dose and duration; thioridazine and chlorpromazine can also produce similar changes. Understanding these risks helps guide safe prescribing.

Multiple Choice

Bull's eye maculopathy is associated with which drugs?

Bull's eye maculopathy is a pattern of drug-induced retinal toxicity indicating damage to the retinal pigment epithelium and surrounding photoreceptors around the fovea, producing a circular ring around a relatively preserved center. Chloroquine and hydroxychloroquine are classic culprits; with long-term or high-dose use, these drugs accumulate in the RPE and outer retina, leading to parafoveal cell loss and the characteristic bull's-eye appearance on examination and imaging. The risk rises with higher dose, longer duration, kidney function issues, and existing retinal changes. Thioridazine, a phenothiazine antipsychotic, is well known for causing pigmentary retinopathy and can present with a bull's-eye maculopathy pattern, especially at higher cumulative doses. Chlorpromazine, another phenothiazine, can also cause retinal pigment changes, and although less common, bull's-eye configurations have been reported. Since all of these drugs can be associated with bull's eye maculopathy, all of the above is the best answer.

Bull’s-eye maculopathy is a striking, almost cinematic find you don’t forget once you’ve seen it. It’s the kind of retinal pattern that makes clinicians pause, lean in, and connect the dots between a medication history and a patient’s churning visual symptoms. The “bull’s-eye” name comes from the way the central fovea stays relatively preserved while a ring of outer retina and retinal pigment epithelium around it bears the brunt of toxicity. It’s a reminder that the eyes are a sensitive barometer of systemic drug effects, and that certain medicines can leave a legacy right where we need sharp, precise vision to navigate the world.

What causes that ring to form? In drug-induced bull’s-eye maculopathy, the drama unfolds in the retina’s outer layers, especially the retinal pigment epithelium (RPE) and the photoreceptors around the fovea. The fovea—the tiny pit in the center of the macula that does most of our fine vision—gets protected at first, while the surrounding parafoveal area begins to suffer. Over time, if exposure continues, the ring can brighten and widen, and the central vision can be affected as the disease progresses. The pattern isn’t unique to one drug; several agents have been implicated, sometimes acting alone, sometimes in combination with patient-specific factors like kidney function, age, or preexisting retinal changes.

Let’s walk through the medications most commonly linked to this pattern, and what makes them special in the eye. It’s a short list, but the stories behind each drug help explain why bull’s-eye maculopathy shows up.

  • Chloroquine and hydroxychloroquine: the classic culprits

Think of chloroquine and its cousin hydroxychloroquine as longtime travelers in the retina. They accumulate in the RPE and outer retina, especially with higher daily doses and longer durations. The risk isn’t just about how much you take, but also how long you’ve been taking it. The mechanism isn’t perfectly understood, but it’s believed that these drugs interfere with lysosomal function in the RPE and disrupt photoreceptor turnover. The cumulative burden—dose times duration—correlates with the likelihood of seeing parafoveal loss and the telltale bull’s-eye pattern on exam and imaging. Regular monitoring is a must for anyone on these meds, because early changes can be subtle, and once the pattern is established, some damage can be irreversible.

  • Thioridazine: pigmentary retinopathy with a twist

Thioridazine sits in a different branch of pharmacology, a phenothiazine antipsychotic with a long history. It’s notorious for pigmentary retinopathy, which can present as a bull’s-eye maculopathy, particularly when exposure is high or cumulative. The retina can absorb the pigmentary changes that radiate around the fovea, producing that ring-like appearance. Because thioridazine isn’t a first-line agent anymore in many places due to its broader side-effect profile, the pattern becomes a cautionary tale about dose awareness and retinal surveillance when any drug in this class is considered.

  • Chlorpromazine: another phenothiazine with retinal whispers

Chlorpromazine, the older sibling in the phenothiazine family, also carries the risk of retinal pigment changes. While bull’s-eye configurations are less common with chlorpromazine compared to thioridazine, they have been reported. The underlying message remains the same: any drug that sits in the retina and interferes with cellular maintenance can, over time, choreograph a pigmentary dance that ends in a recognizable maculopathy pattern.

  • All of the above: a practical takeaway

When you’re looking at drug-induced bull’s-eye maculopathy, the safest, most accurate framing is that it can be associated with multiple agents across different drug classes. The “all of the above” reality isn’t a trivia answer so much as a clinical reminder: keep a wide lens about potential culprits, especially when a patient’s history spans medications known to affect the retina.

How does the bull’s-eye pattern actually look and feel in the clinic? What should you be looking for when you examine or image the retina?

  • Fundoscopic and autofluorescence hallmarks

The central fovea often appears relatively intact, with a surrounding ring where the pigmentation and photoreceptor integrity have eroded. You may notice subtle changes in color or clarity around the macula. Autofluorescence imaging, which maps lipofuscin accumulation in the RPE, often highlights the classic ring as a distinct hyper- or hypo-autofluorescent zone around the preserved center. The ring’s appearance can evolve as the disease progresses, sometimes widening or changing intensity.

  • Optical coherence tomography (OCT) clues

OCT is the workhorse for structural detail. In bull’s-eye maculopathy, you’ll typically see disruption of the outer retinal layers—the ellipsoid zone (the photoreceptor inner segment band) and the interdigitation zone—around the parafoveal area while the foveal center remains relatively spared early on. That pattern mirrors the functional reality: central vision can be affected later, as the inner retinal architecture becomes compromised.

  • Visual function and symptoms

Patients might report minimal symptoms early on, with subtle metamorphopsia or slight blur. As changes accumulate, central vision may decline, colors might look washed out, and reading or recognizing faces can become more challenging. The observer’s job is to correlate these subjective experiences with objective findings, using imaging as a bridge between the two worlds.

Who’s at greater risk, and what can be done to minimize trouble?

  • Dose, duration, and pharmacovigilance

As with many drug-related ocular effects, dose and duration matter. The risk climbs with higher cumulative exposure, but it isn’t a simple straight line—there are individual susceptibilities. Kidney function can influence how long these drugs stay active in the body, and preexisting retinal changes can lower the threshold for toxicity. In practice, this means clinicians take a careful medication history, consider baseline retinal assessment before starting therapy (when feasible), and schedule ongoing surveillance that matches the risk profile.

  • Screening and monitoring strategies

For chloroquine or hydroxychloroquine, screening guidelines emphasize a baseline exam and then serial follow-ups. Modern protocols often include OCT and autofluorescence to catch early changes before functional vision is severely impacted. For phenothiazines like thioridazine and chlorpromazine, historical data taught us that retinal pigment changes can result from cumulative exposure; while these agents aren’t as commonly used for certain conditions today, awareness remains valuable if they’re encountered in a patient’s med list.

  • Modifying therapy and patient-centered decisions

If signs of bull’s-eye maculopathy emerge, the clinician weighs the benefits of continuing therapy against potential retinal harm. In some cases, dose reduction, switching to a different medication, or enhancing monitoring may be appropriate. The key is shared decision-making—patients deserve to know what the retinal changes might mean for daily activities and long-term vision, and clinicians need to align treatment choices with those realities.

A few practical notes that often spark curiosity

  • The pattern isn’t always perfectly circular

Bull’s-eye maculopathy is a spectrum, and not every patient will show a textbook ring. Some will have irregular retinal pigment changes around the fovea, or the ring may appear asymmetric. That’s okay—patterns can vary, and imaging helps confirm the overarching theme of parafoveal toxicity.

  • Not every pigmented retina means toxicity

Pigmentary changes happen for a bunch of reasons, including inherited conditions or age-related changes. The clinical context—drug history, onset of symptoms, and imaging features—helps distinguish drug-induced bull’s-eye patterns from other pigmentary retinopathies.

  • A word about patient education

Patients often appreciate plain-language explanations. Describing the bull’s-eye as a “tiny area around the center that’s affected by the drug’s effect on the retina” makes it tangible. Emphasize that early detection matters: adjusting the medication plan can help preserve function over time.

Why this topic matters beyond the eye exam

Think about the broader lesson: medications, even when they do wonderful things for systemic health, can cast a shadow on vision if we’re not paying attention. The retina is a delicate canvas that responds to long-game exposure. That’s why collaboration between prescribers, ophthalmologists, and patients is so important. When we share information—dose history, duration, evolving symptoms—we give the retina a better chance to dodge lasting damage.

A quick tour through memorable takeaways

  • Bull’s-eye maculopathy is a recognizable pattern of retinal toxicity that rings a bell around the fovea.

  • Chloroquine and hydroxychloroquine are classic offenders, with risk rising with dose and duration, especially in people with kidney issues or preexisting retinal changes.

  • Thioridazine and chlorpromazine, though used less frequently for some conditions today, have also been linked to pigmentary retinopathy and bull’s-eye patterns.

  • Imaging, especially OCT and autofluorescence, is essential for early detection and monitoring.

  • Management hinges on balancing therapeutic benefits with potential retinal harm, guided by patient values and preferences.

A final thought that ties back to everyday clinical practice

In the end, bull’s-eye maculopathy isn’t just a sign in a textbook. It’s a reminder to look closely at what medicine does to the body as a whole, including the eyes. It’s about recognizing patterns, listening to patients’ experiences, and navigating a path that respects both the science and the lived realities of vision. If you’ve ever watched a patient describe how a simple task—like reading a label or recognizing a face—has grown a touch harder over time, you’ll know why this topic isn’t merely theoretical. It’s practical, human, and deeply relevant to preserving the everyday gift of sight.